Bilateral Optic Neuritis Secondary to Nivolumab Therapy: A Case Report

Medicina (Kaunas). 2018 Nov 6;54(5):82. doi: 10.3390/medicina54050082.

Abstract

Pediatric glioblastoma multiforme is an uncommon and highly mortal brain cancer. New therapeutic treatments are being intensively investigated by researchers in order to extend the survival of patients. The immune checkpoint inhibitor nivolumab in the treatment of pediatric glioblastoma multiforme is currently under review; it is a human immunoglobulin G4 monoclonal antibody that works against the programmed cell death protein 1 receptor, designed to enhance an immunologic reaction against cancer cells. Herein, we describe the first report of a bilateral optic neuritis induced by nivolumab in a grade 4 glioblastoma multiforme patient.

Keywords: glioblastoma multiforme; nivolumab; optic neuritis.

Publication types

  • Case Reports

MeSH terms

  • Adrenal Cortex Hormones / administration & dosage
  • Adrenal Cortex Hormones / therapeutic use
  • Antineoplastic Agents, Immunological / administration & dosage
  • Antineoplastic Agents, Immunological / adverse effects*
  • Antineoplastic Agents, Immunological / therapeutic use
  • Autoimmune Diseases / immunology
  • Brain Neoplasms / diagnostic imaging
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / radiotherapy
  • Brain Neoplasms / surgery
  • Child
  • Disease Progression
  • Glioblastoma / diagnostic imaging
  • Glioblastoma / drug therapy*
  • Glioblastoma / radiotherapy
  • Glioblastoma / surgery
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Nivolumab / administration & dosage
  • Nivolumab / adverse effects*
  • Nivolumab / therapeutic use
  • Optic Neuritis / diagnostic imaging*
  • Optic Neuritis / immunology*

Substances

  • Adrenal Cortex Hormones
  • Antineoplastic Agents, Immunological
  • Nivolumab